CD3 News and Research

RSS

Microscopic peptide droplets reduce colorectal tumor growth in mice

Scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed microscopic peptide droplets that deliver large amounts of gene-silencing molecules into cancer and immune cells, reducing the growth of hard-to-treat colorectal tumours by about 67 per cent in mice.

3 Sep 2026

Multifunctional nanoplatform addresses three key barriers to effective TNBC immunotherapy

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15-20% of all cases.

21 Aug 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

Engineered CAR-T cells offer potential rheumatoid arthritis cure

For the 18 million people living with rheumatoid arthritis, disease management currently means a lifetime of injections-a reality that new research from Tsinghua University may soon begin to change.

22 Jun 2026

Microenvironmental CTHRC1 protein promotes colorectal cancer tumor growth

A new research paper was published in Volume 17 of Oncotarget on May 20, 2026, titled "Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer."

2 Jun 2026

New T-cell engager therapy shows effectiveness in advanced solid tumors

A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD Dresden University of Technology will present clinical results for the first time on May 31, 2026, at this year’s annual meeting of the American Society of Clinical Oncology (ASCO) regarding a new cancer immunotherapy for the treatment of advanced tumors.

1 Jun 2026

Tumor microenvironment markers forecast immunotherapy response in rare cancers

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

20 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic capacity, cytokine production, and persistence after activation. The study identifies triglyceride-rich chylomicrons as key drivers of this effect, suggesting nutritional timing may matter for immune monitoring, vaccination research, and cell-therapy manufacturing.

30 Apr 2026

Hepatitis C infection associated with reduced portal insulin levels

Insulin resistance is a common extrahepatic manifestation of hepatitis C virus (HCV) infection (HCVi), but its mechanism is poorly understood.

28 Apr 2026

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a therapeutic effect on rheumatoid arthritis (RA) by promoting the degradation of acyl coenzyme A thioesterase 1 (ACOT1) via the ubiquitin‒proteasome pathway and restoring the homeostasis of unsaturated fatty acids.

25 Apr 2026

How the immune system may influence Alzheimer’s, Parkinson’s, and related diseases

This review argues that neurodegeneration is shaped not only by toxic protein buildup but also by immune signaling, with microglia and T cells able to either protect the brain or worsen damage depending on context. It also highlights aging, head injury, and viral infection as major forces that reshape CNS immunity and may influence disease progression and future treatment strategies.

16 Apr 2026

African health expert: genomic sequencing enables near real-time pathogen detection

Advanced genomic sequencing techniques, like mNGS, are essential for accurate pathogen detection, crucial for effective outbreak response and patient care.

From BGI Genomics 15 Apr 2026

New method uses biomarkers to determine a person's biological age

Aging is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a method that uses biomarkers to determine a person's biological age - a valuable tool for research on ageing and the development of new approaches in preventive medicine.

19 Mar 2026

Distinct spatial tumor–immune ecosystems predict lung cancer treatment response

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

5 Mar 2026

Remote-controlled CAR T cells offer safer cancer therapy

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers.

19 Feb 2026

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

From WuXi Biologics 27 Jan 2026

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

Urolithin A recharges aging immune cells and boosts mitochondrial fitness in midlife adults

Urolithin A, a natural postbiotic known to trigger mitophagy, rejuvenated key immune cell functions in healthy middle-aged adults after 28 days. The trial showed a shift toward a youthful, energy-efficient CD8⁺ T-cell profile and enhanced bacterial clearance without inflammatory side effects.

3 Nov 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025